Cart
Tyrosine Kinase/Adaptors Ephrin Receptor

Ephrin Receptor

Eph receptors (Ephs, after erythropoietin-producing human hepatocellular receptors) are a group of receptors that are activated in response to binding with Eph receptor-interacting proteins (Ephrins). Ephs form the largest known subfamily of receptor tyrosine kinases (RTKs). Both Eph receptors and their corresponding ephrin ligands are membrane-bound proteins that require direct cell-cell interactions for Eph receptor activation. Eph/ephrin signaling has been implicated in the regulation of a host of processes critical to embryonic development including axon guidance, formation of tissue boundaries, cell migration, and segmentation. Additionally, Eph/ephrin signaling has recently been identified to play a critical role in the maintenance of several processes during adulthood including long-term potentiation, angiogenesis, and stem cell differentiation and cancer.
Cat No. product name
TP1895L1 KYL acetate(676657-00-4 free base) EphA4 receptor tyrosine kinase inhibitor (Kd = 0.8 μM); inhibits EphA4-EphrinA5 interactions (IC50 = 6.34 μM). Prevents AβO induced synaptic damage, dendritic...
T19487 NVP-BHG712 isomer NVP-BHG712 isomer shows conserved non-bonded binding to EPHA2 and EPHB4.
TQ0166 Tesevatinib Tesevatinib is an orally available, multi-target tyrosine kinase inhibitor (IC50s: 0.3, 16, 1.5, 8.7, and 1.4 nM for EGFR, ErbB2, KDR, Flt4, and EphB4).
T5452 Ehp-inhibitor-2 Ehp-inhibitor-2 is an Eph family tyrosine kinase inhibitor targeting Eph receptors.
T5451 Ehp-inhibitor-1 Ehp-inhibitor-1 is an Eph family tyrosine kinase inhibitor targeting Eph receptors.
T4344 ALW-II-41-27 ALW-II-41-27, an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy.
T6348 NVP-BHG712 NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c...
T3476 JI101 JI-101 is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor receptor β (P...
T1448L Dasatinib monohydrate Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoti...
T2456 Tivozanib Tivozanib is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplasti...
KYL acetate(676657-00-4 free base)
TP1895L1CAS TP1895L1
EphA4 receptor tyrosine kinase inhibitor (Kd = 0.8 μM); inhibits EphA4-EphrinA5 interactions (IC50 = 6.34 μM). Prevents AβO induced synaptic damage, dendritic...
NVP-BHG712 isomer
T19487CAS 2245892-85-5
NVP-BHG712 isomer shows conserved non-bonded binding to EPHA2 and EPHB4.
Tesevatinib
TQ0166CAS 781613-23-8
Tesevatinib is an orally available, multi-target tyrosine kinase inhibitor (IC50s: 0.3, 16, 1.5, 8.7, and 1.4 nM for EGFR, ErbB2, KDR, Flt4, and EphB4).
Ehp-inhibitor-2
T5452CAS 861249-77-6
Ehp-inhibitor-2 is an Eph family tyrosine kinase inhibitor targeting Eph receptors.
Ehp-inhibitor-1
T5451CAS 861249-59-4
Ehp-inhibitor-1 is an Eph family tyrosine kinase inhibitor targeting Eph receptors.
ALW-II-41-27
T4344CAS 1186206-79-0
ALW-II-41-27, an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy.
NVP-BHG712
T6348CAS 940310-85-0
NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c...
JI101
T3476CAS 900573-88-8
JI-101 is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor receptor β (P...
Dasatinib monohydrate
T1448LCAS 863127-77-9
Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoti...
Tivozanib
T2456CAS 475108-18-0
Tivozanib is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplasti...